QIAD assay for quantitating a compounds efficacy in elimination of toxic Aβ oligomers

Academic Article

Abstract

  • Strong evidence exists for a central role of amyloid β-protein (Aβ) oligomers in the pathogenesis of Alzheimer s disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, to quantify the effect of any compound on the Aβ aggregate size distribution. Applying QIAD, we studied the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZAβ3W, the D-enantiomeric peptide D3 and its tandem version D3D3 on Aβ aggregation. The predictive power of the assay for in vivo efficacy is demonstrated by comparing the oligomer elimination efficiency of D3 and D3D3 with their treatment effects in animal models of Alzheimeŕs disease.
  • Published In

  • Scientific Reports  Journal
  • Digital Object Identifier (doi)

    Author List

  • Brener O; Dunkelmann T; Gremer L; Van Groen T; Mirecka EA; Kadish I; Willuweit A; Kutzsche J; Jürgens D; Rudolph S
  • Volume

  • 5